Serum Resistin Level and Its Receptor Gene Expression in Liver Biopsy as Predictors for the Severity of Nonalcoholic Fatty Liver Disease

Mona Hegazy, Soheir Abo-Elfadl, Abeer Mostafa, Magdy Ibrahim, Laila Rashed, Ahmed Salman, Mona Hegazy, Soheir Abo-Elfadl, Abeer Mostafa, Magdy Ibrahim, Laila Rashed, Ahmed Salman

Abstract

Background: Liver histology remains the gold standard for assessing nonalcoholic fatty liver disease (NAFLD). Noninvasive serological markers have been developed to evaluate steatosis to avoid biopsy. In NAFLD patients, serum resistin was higher than those in control lean and obese patients.

Objective of the study: To investigate serum resistin and its receptor gene expression in liver biopsy as predictors for NAFLD severity.

Patients and methods: This study was conducted on 54 obese patients, with suspected fatty liver by ultrasound (excluding diabetic, alcoholic, hepatitis C virus antibody (HCVAb) or hepatitis B surface antigen (HBsAg) positive patients). They were subjected to anthropometric measurements, laboratory studies including serum resistin, abdominal ultrasonography (US) and liver biopsy. The 15 lean subjects were included as a control group. According to biopsy results, patients were subdivided into nonalcoholic steatohepatitis (NASH) group (46 patients) and non-NASH group (8 patients).

Results: Significantly higher levels of resistin were detected in NAFLD patients compared to control subjects (p = 0.0001). Also, higher levels of resistin were recorded in NASH group compared to the non-NASH group; however, the difference was not statistically significant (p = 0.584). Serum alanine aspirate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT) were higher in NASH patients than non-NASH group (p = 0.223, p = 0.005 and p = 0.006 respectively). Abdominal US showed high sensitivity in NAFLD diagnosis (sensitivity of sonar in detecting steatosis grade compared to biopsy was 61% in grade 1, 25% in grade 2 and 75% in grade 3).

Conclusion: Serum resistin can be combined with other noninvasive markers to predict the presence of NASH as an alternative to liver biopsy.How to cite this article: Hegazy M, Abo-Elfadl S, Mostafa A, Ibrahim M, Rashed L, Salman A. Serum Resistin Level and Its Receptor Gene Expression in Liver Biopsy as Predictors for the Severity of Nonalcoholic Fatty Liver Disease. Euroasian J Hepato-Gastroenterol 2014;4(2):59-62.

Keywords: Liver biopsy.; NAFLD; Obesity; Resistin.

Conflict of interest statement

Source of support: Nil Conflict of interest: None

References

    1. Desai P, Tamarapu Parthasarathy P, Galam L, Lockey R, Kolliputi N. A new role for inflammasomes: sensing the disturbances in non-alcoholic fatty liver disease. Front Physiol. 2013 Jul 1;4:156.
    1. Baranova A, Tran TP, Afendy A, Wang L, Shamsaddini A, Mehta R, Chandhoke V, Birerdinc A, Younossi ZM. Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). J Transl Med. 2013 May 31;11:133.
    1. Parkash O, Hamid S. Are we ready for a new epidemic of under recognized liver disease in South Asia especially in Pakistan? Non-alcoholic fatty liver disease. J Pak Med Assoc. 2013 Jan;63(1):95–99.
    1. Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Noninvasive investigations for non-alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol. 2010 Oct 1;16(38):4784–4791.
    1. Ye H, Zhang HJ, Xu A, Hoo RL. Resistin production from adipose tissue is decreased in db/db obese mice, and is reversed by rosiglitazone. PLoS One. 2013 Jun 12;8(6):e65543.
    1. Gupta V, Singh AK, Gupta V, Kumar S, Srivastava N, Jafar T, Pant AB. Association of circulating resistin with metabolic risk factors in Indian females having metabolic syndrome. Toxicol Int. 2011 Jul;18(2):168–172.
    1. Gandhi H, Upaganlawar A, Balaraman R. Adipocytokines: The pied pipers. J Pharmacol Pharmacother. 2010 Jan;1(1):9–17.
    1. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab. 2003 Nov;88(11):5452–5455.
    1. Kleiner DE, Brunt EM, Van Natta M, Behlling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A et al. Design and validation of a histologic scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 Jun;41(6):1313–1321.
    1. Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, Neuschwander-Tetri BA. NASH clinical research network a list of members of the nonalcoholic steatohepatitis clinical research network can be found in the appendix. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinico-pathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009 Mar;49(3):809–820.
    1. VanGuilder HD, Vrana KE, Freeman WM. Twenty-five years of quantitative PCR for gene expression analysis. Biotech- niques. 2008 Apr;44(5):619–626.
    1. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 [(-delta-delta C (T)] method. Methods. 2001 Dec;25(4):402–408.
    1. Marchesini G, Moscatiello S, Agostini F, Villanova N, Festi D. Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opin Emerg Drugs. 2011 Mar;16(1):121–36.
    1. Jiang LL, Li L, Hong XF, Li YM, Zhang BL. Patients with nonalcoholic fatty liver disease display increased serum resist in levels and decreased adiponectin levels. Eur J Gastroenterol Hepatol. 2009 Jun;21(6):662–666.
    1. Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G, Donnini D, Faggian D, Mussap M, Plebani M et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab. 2006 Mar;91(3):1081–1086.
    1. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, Rafig N, Goodman Z, Chandhoke V et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg. 2008 Nov;18(11):1430–1437.
    1. Zhao CY, Yan L, Wang YD, Wang W, Zhou JY, Zhen Z. Role of resistin in inflammation of hepatocytes in non-alcoholic steatohepatitis. Zhonghua Gan Zang Bing Za Zhi. 2009 Sep;17(9):683–687.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera